As described below, these studies led to the identification of a diverse set of compounds and putative drug targets that affect tau inclusion formation in primary neurons, providing a valuable resource for further investigation of potential targets and small molecules that might ultimately lead to new drug discovery opportunities for the treatment of AD and related tauopathies. Here, MAPT is linked to Alzheimer disease.